Kimberly-Clark has asked EU regulators permission for its proposed $40 billion takeover of Tylenol maker Kenvue, documents on the EU Commission's website showed.
KVUE's Q2 sales and earnings miss estimates, but organic growth improved as Skin Health and Beauty led a broader recovery.
Kimberly-Clark is rated Buy, supported by a strong innovation pipeline, international growth, and upside from the Kenvue acquisition. KMB faces transient headwinds in North America and China, but these are expected to abate, with management forecasting mid- to high-single-digit EPS CAGR from 2026–2028. The Kenvue deal will initially dilute EPS, but synergy realization is tracking ahead of plan, with $1.9B cost and $1.4B revenue synergy targets.
| Household Products Industry | Consumer Staples Sector | Kirk L. Perry CEO | XMIL Exchange | US49177J1025 ISIN |
| US Country | 21,890 Employees | 12 Aug 2026 Last Dividend | - Last Split | 4 May 2023 IPO Date |
Kenvue Inc. is a global consumer health firm that offers a wide range of healthcare products through its diverse operational segments: Self Care, Skin Health and Beauty, and Essential Health. Founded in 2022 and headquartered in Skillman, New Jersey, Kenvue Inc. delivers a comprehensive portfolio of products designed to improve the wellness and health of consumers around the world. By leveraging well-known brands across its segments, Kenvue provides solutions for everyday health concerns, from pain relief and cold prevention to skincare and baby care.